No5 barrister at the head of the debate on pricing of rare drugs

Wed, 17 Nov 2010

No5 barrister David Lock is quoted in this week’s edition of the British Medical Journal in connection with the controversy over the pricing of rare drugs, which has seen 20 leading doctors write in protest to the Prime Minister about the conduct of drug companies.
 
Drug companies are attempting to persuade the NHS to prescribe expensive drugs which have an EU “marketing authorisation” in preference to much cheaper, generic drugs which have a similar clinical effect but have no marketing authorisation.
 
David has given advice to the NHS, which the NHS then chose to publish, that it would be likely to be lawful for NHS bodies to refuse to allow doctors to prescribe branded drug where there is a generic drug which delivers similar clinical outcomes at a lower cost. 
 
 

Related articles

Pilots may be the subject of a prosecution when flying single engine aircraft in the vicinity of major conurbations, as distinct from flying over a city centre....

Date: Mon, 04 Jan 2010
David Lock of No5 chambers is representing Cambridgeshire Primary Care Trust in the Inquest into the death of David Grey and Iris Edwards, who both died following treatment by a German locum doctor, Dr Ubani....

Date: Thu, 14 Jan 2010
Ralph Lewis QC leads Gordon Wignall, Henry Pitchers and Matthew Brunning in a Group Litigation case....

Date: Thu, 14 Jan 2010